SpaceX Files IPO Papers Ahead of Next Starship Test Flight
SpaceX submitted IPO registration documents on Wednesday. The filing highlights Starship as central to future revenue plans while noting ongoing development delays.
ForbesSpaceX filed IPO registration documents on Wednesday. The filing lists more than $15 billion spent on Starship development and current annual revenue of $18 billion with nearly $5 billion in losses. Starship is described in the filing as a fully reusable heavy-lift rocket larger than the Saturn V.
The company states that next-generation Starlink satellites, proposed orbital data centers, and NASA lunar missions all require Starship launches.
The next Starship test flight had been scheduled for earlier this week but was delayed. It is now expected to launch within hours of the filing becoming public. The prospectus notes in bold text that any failure or delay in Starship development would limit the company’s ability to deploy next-generation satellites and orbital AI compute systems.
8 billion valuation. The company has one autophagy drug in clinical trials and plans two additional programs for 2026 and 2027. NASA Administrator Jared Isaacman said he expects China to conduct a crewed lunar flyby mission next year. The agency also announced a reorganization consolidating several departments.
Key Facts
Story Timeline
3 events- Wednesday
SpaceX filed IPO registration documents.
1 sourceForbes - This week
Starship test flight delayed from earlier schedule.
1 sourceForbes - This week
Retro Biosciences raised funding at $1.8 billion valuation.
1 sourceForbes
Potential Impact
- 01
Outcome of the next Starship test may affect timing of next-generation satellite deployments.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…